Improving Healthcare, Reducing Costs, Saving Lives
|Pre-sale Time:||31 Aug, 2018 - 1 Nov, 2018|
|ICO Time:||1 Nov, 2018 - 30 Nov, 2018|
|Available for sale:||250,000,000 CTKN (50%)|
January 2016 - Curaizon™ begins development of drug-adherence technologies. Development of CuraServe™ begins in collaboration with Gateway Technolabs.
January 2017 - CuraServe™ demonstrated to National Health Service
June 2017 - Internal testing & Review
October 2017 - For patients, providers and health services
November 2017 - Offering preparation begins
February 2018 - First phase of CuraData™ available
August 1st 2018 -
November 2018 -
November 2018 - Live integration with Curaizon's™ data
February 2019 - Commercialization of platform offering full access to our big data and advanced analytics
March 2019 - Curaizon’s adherence technology, CuraServe™, is made available to national health services
April 2019 - Curaizon™ rolls out its adherence technologies to target markets, gaining traction creating mass data
July 2019 - As the user-base increases, our data dramatically expands and matures, providing significant growth in value
2020 - Fully integrated and full feature data trading and collaboration platform with patent numbers estimated 90+ million
We’re revolutionizing healthcare and improving drug-adherence through big data analytics delivered via the blockchain.
Medicines are our most cost‐effective health intervention and represent the first line of defense against chronic and long‐term conditions. Unfortunately, far too many people fail to take their medications properly and the resulting personal and financial costs are staggering. Despite a worldwide recognition of the seriousness of the issue (also called drug non‐adherence), there has been no significant change for the last 30 years.
• Worldwide drug non‐adherence results in approximately $700 billion in additional healthcare costs.
• Pharmaceutical companies lose more than $630 billion in revenue annually to patient non‐adherence and the amount lost is increasing by 13% per year.
CuraServe™ is a complete healthcare ecosystem that improves drug adherence and brings game‐changing benefits to patients and healthcare providers. We use a series of outreach tools and messages, supported by predictive modeling and
behavioral analytics, to increase the rate of drug adherence. As our CuraServe™
solution helps patients, it’s also generating a vast amount of patient data. That data is then anonymized and made available through CuraData™. The only way that pharmaceutical companies, academics and researchers can access this data by purchasing CuraTokens™. Our data is the first‐of‐its‐kind insight into real‐time patient behavior and adherence. CuraData™ will finally give the health and
pharmaceutical industries the tools they have been looking for to bring about the change patients need. Our value‐based approach to a simple, accessible, yet
valuable exchange of data and analysis will revolutionize healthcare.
Healthcare is changing forever and CuraServe™ stands at the cutting edge of this transformation. Curaizon™ is the UK‐based company that has developed CuraServe™.
The total number of potential users of our platform include all of the patients covered by national health services across the world. This is a total of 1.4 Billion people and growing.
• Better Patient Outcomes
• Better Research
• Better Healthcare
• Money Saved
Projected revenue of $800+M and net profit of $660+M in year-3
Put this code to your website